Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cadence Design Systems Inc (CDNS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Cadence Design Systems IncTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Cadence Design Systems Inc vs Recursion Pharmaceuticals Inc — how do they compare? Cadence Design Systems Inc trades at $376.5 (market cap $104.24B), while Recursion Pharmaceuticals Inc trades at $3.37 (market cap $1.75B). The key difference: Cadence Design Systems Inc is far larger — about 59.6× Recursion Pharmaceuticals Inc's market cap, and Cadence Design Systems Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

CDNSRXRX
Market Cap
$104.24B$1.75B
Sector
TechnologyHealth
52-Week High
$416.39$6.79
52-Week Low
$265.66$2.84
Enterprise Value
$105.91B$1.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cadence Design Systems Inc

Cadence Design Systems (CDNS) trades at $377.92, down 1.63% on the day, with strong analyst support (84% buy ratings) and a $400.25 consensus price target. The stock shows bullish technical signals with support at $373 and resistance at $385. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 results expected on July 27, 2026. Revenue growth remains robust, climbing from $3.6B in 2022 to $5.3B in 2025, though profit margins have moderated slightly.

CDNS presents a compelling growth story driven by AI and semiconductor design demand, with upside to analyst targets. However, high valuation multiples (P/E 88.09, P/S 18.68) pose risks if growth slows. Key near-term catalyst is Q2 earnings; sustained execution is critical to justify premium valuation amid competitive pressures.

Recursion Pharmaceuticals Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cadence Design Systems Inc

Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enable system-level analysis and verification solutions. Cadence's comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers, alongside secular digitalization of various end markets, benefits EDA vendors like Cadence.

Read more on CDNS

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX